MPM BioImpact LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001687078
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 32 positions · Total reported value $374.60M · Top-10 concentration 61.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 81.2% · 7 new · 21 cut · 11 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2023 13F filing, MPM BioImpact LLC disclosed 32 equity positions with a combined reported value of $374.60M. The filing implies a focused portfolio: its ten largest positions account for 61.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2023 were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M). By sector, the heaviest allocations are Health Care 69.3%, Materials 1.1%.
Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions.
The largest new positions opened in Q3 2023 were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
- CGEM CULLINAN THERAPEUTICS INC · $69.22M
- OLMA OLEMA PHARMACEUTICALS INC · $22.94M
- GERN GERON CORP · $22.71M
- RPTX REPARE THERAPEUTICS INC · $19.81M
- ITOS ITEOS THERAPEUTICS INC · $19.12M
- NTLA INTELLIA THERAPEUTICS INC · $17.22M
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · $16.77M
- IOVA IOVANCE BIOTHERAPEUTICS · $14.96M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-106989 (status: Approved), registered 2016-01-04
- Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 14 private funds, of which 3 hedge funds
Portfolio Structure
- 37 positions · $1.64B reported value (Q2 2026)
- Top 10 holdings = 55.3% of reported value
- Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
- Average position size: $44.32M
Sector Tilt
- Health Care 98.7%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
7.65M | $69.22M | 18.48% | New | |
| 2 |
|
1.86M | $22.94M | 6.12% | New | |
| 3 |
|
10.71M | $22.71M | 6.06% | New | |
| 4 |
|
1.64M | $19.81M | 5.29% | New | |
| 5 |
|
1.75M | $19.12M | 5.10% | New | |
| 6 |
|
544.64K | $17.22M | 4.60% | New | |
| 7 |
|
294.19K | $16.77M | 4.48% | New | |
| 8 |
|
3.29M | $14.96M | 3.99% | New | |
| 9 |
|
479.05K | $14.25M | 3.80% | New | |
| 10 |
|
527.46K | $13.32M | 3.56% | New | |
| 11 |
|
230.76K | $11.63M | 3.11% | New | |
| 12 |
|
857.94K | $11.38M | 3.04% | New | |
| 13 |
|
1.35M | $11.37M | 3.04% | New | |
| 14 |
|
656.72K | $10.81M | 2.89% | New | |
| 15 |
|
610.77K | $9.11M | 2.43% | New | |
| 16 |
|
53.21K | $9.00M | 2.40% | New | |
| 17 |
|
716.14K | $8.71M | 2.33% | New | |
| 18 |
|
273.41K | $7.57M | 2.02% | New | |
| 19 |
|
3.99M | $7.42M | 1.98% | New | |
| 20 |
|
664.22K | $6.84M | 1.83% | New | |
| 21 |
|
93.59K | $6.54M | 1.75% | New | |
| 22 |
|
40.86K | $5.97M | 1.59% | New | |
| 23 |
|
577.96K | $5.57M | 1.49% | New | |
| 24 |
|
2.39M | $5.11M | 1.36% | New | |
| 25 |
|
552.85K | $4.94M | 1.32% | New | |
| 26 |
|
200.00K | $4.58M | 1.22% | New | |
| 27 |
|
5.10M | $3.97M | 1.06% | New | |
| 28 |
|
255.32K | $3.92M | 1.05% | New | |
| 29 |
|
347.33K | $3.60M | 0.96% | New | |
| 30 |
|
325.00K | $3.60M | 0.96% | New | |
| 31 |
|
326.92K | $1.37M | 0.37% | New | |
| 32 |
|
319.67K | $1.29M | 0.34% | New | |
FAQ
What did MPM BioImpact LLC buy in 2023-Q3?
In its 2023-Q3 13F filing, MPM BioImpact LLC reported 32 equity positions worth $374.60M in aggregate; its largest disclosed positions were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M).
How large is MPM BioImpact LLC's portfolio?
MPM BioImpact LLC reported $374.60M of long equity holdings across 32 positions as of 2023-Q3. Top-10 holdings account for 61.5% of reported value.
What is MPM BioImpact LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.